Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY, USA.
Dermatology. 2017;233(5):396-398. doi: 10.1159/000480379. Epub 2017 Sep 28.
There are limited data evaluating the utilization of dermatologists for the care of patients with hidradenitis suppurativa.
To determine the utilization of the dermatology ambulatory encounter among hidradenitis suppurativa patients, and to evaluate whether utilization varies by insurance status.
This was a retrospective cohort analysis in an adult population sample of 42,030 hidradenitis suppurativa patients with either private or public health insurance who were identified by a validated scheme using SNOMED-CT terminology. The primary outcome was a dichotomous variable defined as having at least 1 ambulatory encounter with a dermatologist over a 3-year period.
Overall, 21.8% (9,170/42,020) of the hidradenitis suppurativa patients had at least 1 ambulatory encounter with a dermatologist. This proportion did not significantly vary between patients with private insurance (22%), Medicaid (21.6%), and Medicare (21.7%).
Utilization of the ambulatory dermatology encounter among patients with hidradenitis suppurativa is low in the USA. Factors other than insurance status influence this level of utilization.
评估皮肤科医生在治疗化脓性汗腺炎患者中的作用的数据有限。
确定化脓性汗腺炎患者在皮肤科门诊就诊的利用情况,并评估其是否因保险状况而异。
这是一项回顾性队列分析,纳入了通过 SNOMED-CT 术语验证方案识别的 42030 名化脓性汗腺炎患者,其中包括私人或公共医疗保险患者。主要结局是在 3 年内至少有 1 次与皮肤科医生门诊就诊的二分类变量。
总体而言,21.8%(9170/42020)的化脓性汗腺炎患者至少有 1 次与皮肤科医生的门诊就诊。私人保险(22%)、医疗补助(21.6%)和医疗保险(21.7%)患者之间这一比例无显著差异。
化脓性汗腺炎患者在美国的门诊皮肤科就诊利用率较低。影响这种利用率的因素不仅是保险状况。